28 March 2023 in Medical Herald of the South of Russia
Objective: to investigate the characteristics of pollen sensitization in children with established diagnoses of bronchial asthma (BA) and atopic dermatitis (AD) living in the Rostov region. Materials and methods: patients suffering from BA (n = 53), they made up the first group and patients with AD (n = 65), the second group were examined. All children underwent a comprehensive clinical and laboratory examination. Immunochemiluminescent assay by the Immulight 2000XPi analyzer was used to determine specific IgE. Results: the analysis of the obtained results showed that sensitization to tree pollen was quite often noted - at least a quarter of those examined with BA and about 20% of children with AD had elevated titers of specific IgE to these allergens. The study of the level of specific IgE to meadow grass pollen showed that in the first group an allergic reaction to pollen of bent grass (31.5%), bonfire (33.3%), timothy grass (29.6%) and fescue (28.3%) was noted more often. In the second group, elevated levels of specific IgE were registered in relation to grasses such as bent grass (31.80%), bonfire (27.7%) and timothy grass (21.5%). The highest level of sensitization in patients with respiratory manifestations of allergy was registered in relation to weed pollen: ragweed (40.7%), quinoa (22.2%) and chamomile (14.8%). Conclusion: this study made it possible to identify allergens that play the most important role in the pathogenesis of BA and AD in children living in the Rostov region.
28 February 2024 in Meditsinskiy sovet = Medical Council
Currently, bronchial asthma is a global health problem, due to its high prevalence, economic component, as well as a violation of the social adaptation of children suffering from this disease. This article is devoted to a detailed analysis of the clinical case of a patient born in 2009 with an established diagnosis of Bronchial asthma, atopic form, severe persistent partially controlled course, which initiated therapy with a genetically engineered biological preparation of a humanized monoclonal antibody against IgE – omalizumab. However, in subsequent years, the patient’s condition was unstable, severe seizures were repeated, she was repeatedly hospitalized in the department where infusion therapy was performed and basic therapy was reviewed, dose adjustments and administration regimens of monoclonal antibodies to IgE (omalizumab) were carried out. A retrospective analysis of the results of objective, instrumental and laboratory examinations of the patient was also carried out over the past three years, when the child received the genetically engineered drug omalizumab without interruption. Taking into account the severe course of AD, the lack of control over the disease against the background of basic therapy with combined drugs in combination with therapy with monoclonal antibodies to IgE (omalizumab), it was decided to correct treatment and initiate therapy with a genetically engineered drug, recombinant human monoclonal antibody IgG4 (dupilumab). This clinical example once again shows how personalized the approach should be when prescribing therapy to patients with severe asthma, and also dictates the need to develop new diagnostic methods and management tactics for patients with uncontrolled forms of this disease.